This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2007, p. 2621-2624, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00029-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae{triangledown}

Todd A. Davies,1* Malcolm G. P. Page,2 Wenchi Shang,1 Ted Andrew,1 Malgosia Kania,2 and Karen Bush1

Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey,1 Basilea Pharmaceutica AG, Grenzacherstrasse 487, P.O. Box CH-4005, Basel, Switzerland2

Received 10 January 2007/ Returned for modification 15 February 2007/ Accepted 19 April 2007


arrow
ABSTRACT
 
Ceftobiprole exhibited tight binding to PBP2a in methicillin-resistant Staphylococcus aureus, PBP2x in penicillin-resistant Streptococcus pneumoniae, and PBP3 and other essential penicillin-binding proteins in methicillin-susceptible S. aureus, Escherichia coli, and Pseudomonas aeruginosa. Ceftobiprole also bound well to PBP2 in the latter organisms, contributing to the broad-spectrum antibacterial activity against gram-negative and gram-positive bacteria.


arrow
TEXT
 
Ceftobiprole, an investigational parenteral cephalosporin in phase 3 clinical trials, exhibits a broad spectrum of activity against many clinically important gram-negative and gram-positive bacteria (3, 4, 7, 18, 20, 21, 29). Ceftobiprole is distinguished from other marketed β-lactams by its increased binding to penicillin-binding protein (PBP) 2a (PBP2a) from methicillin-resistant staphylococci (18, 24).

PBPs, the targets of β-lactam antibiotics, are membrane-associated enzymes involved in the last steps of peptidoglycan biosynthesis. The affinities of ceftobiprole for PBPs from Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae were determined.

(This work was presented in part at the 106th General Meeting of the American Society for Microbiology, Orlando, FL, 21 to 25 May 2006; the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16 to 19 December 2005; and the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 29 September 2006.)

MICs were determined according to CLSI methods (5) using Trek Diagnostic Systems (Cleveland, OH) panels, except for ceftobiprole, which was prepared fresh for each assay. E. coli, P. aeruginosa, or S. aureus PBPs were isolated as described previously (18, 30). For S. pneumoniae, whole cells were used. PBPs were labeled with Bocillin FL (Invitrogen, Carlsbad, CA) as described previously (26). S. aureus OC 3726 membranes were preincubated with 1 mg/ml clavulanic acid (USP, Rockville, MD) to saturate all PBPs except PBP2a. PBPs were visualized using a LumiImager (Roche, Indianapolis, IN), and 50% inhibitory concentration (IC50) values were determined using Quantity One software (Bio-Rad, Hercules, CA). P. aeruginosa cell morphology after ceftobiprole exposure was monitored by microscopic examination at a magnification of x1,000. S. pneumoniae pbp1a, pbp2x, and pbp2b were amplified by PCR as described previously (23) and sequenced by ACGT (Wheeling, IL).

For E. coli MC4100, all drugs had good affinity for PBP3, the primary target for monobactams and most cephalosporins (10, 12) (Table 1). Ceftobiprole, ceftriaxone, and cefepime also had good affinity for the essential PBP2 (IC50s of ≤0.6 µg/ml) (Table 1). However, they were at least 20-fold less potent than imipenem (Table 1), for which the primary target is PBP2 in gram-negative bacteria (28). Ceftobiprole and ceftriaxone had IC50s for PBP1a and PBP4 that were approximately 5- to 10-fold lower than those for cefepime and ceftazidime (Table 1). Ceftriaxone and imipenem had greater affinity for PBP1b than the other drugs (Table 1). Only imipenem had high affinity for the nonessential PBP5 and PBP6 (Table 1). Cephalosporins like cefotaxime and ceftazidime target primarily PBP3 and have at least a 50-fold-lower affinity for PBP2 (6, 17, 25). Conversely, the increased affinity of ceftriaxone and cefepime for PBP2 compared to those of other cephalosporins (9, 14, 25) was confirmed in this study and also observed for ceftobiprole (Table 1).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Binding of selected β-lactams to PBPs from gram-negative bacteria

For P. aeruginosa PAO1, the cephalosporins had the greatest affinity for PBP1a and PBP3 (Table 1). Ceftobiprole and cefepime had approximately a 10-fold-higher affinity for PBP4 than ceftazidime (Table 1). Ceftobiprole and imipenem had the lowest IC50 values for PBP1b. Imipenem had the highest affinity for PBP2 (IC50 of 0.1 µg/ml), with ceftobiprole having the greatest affinity (IC50 of 3 µg/ml) among the cephalosporins (Table 1). Cefepime and ceftazidime bound PBP2 with at least an 80-fold-lower affinity than that for PBP3, similar to previously reported data (17, 25). Conversely, ceftobiprole had measurable affinity for PBP2, with an IC50 value 30-fold higher than that for PBP3. The cephalosporins did not bind to PBP5/6 at concentrations as high as 32 µg/ml (Table 1). Aztreonam had highest affinity for PBP3 (Table 1). P. aeruginosa cells grown in the presence of ceftobiprole produced filamentation (Fig. 1), suggesting that PBP3 was the primary target.


Figure 1
View larger version (43K):
[in this window]
[in a new window]

  		FIG. 1. P. aeruginosa PAO1 grown for 1.5 h in (A) nutrient broth alone (control) or (B) nutrient broth containing 1 µg/ml ceftobiprole (1x MIC). Magnification, x1,000.

In methicillin-susceptible S. aureus ATCC 29213, ceftobiprole had good affinity (IC50 of ≤1 µg/ml) for all four PBPs (Table 2). Ceftobiprole had the greatest affinity for PBP3, with an IC50 that was 20-fold lower than that of ceftriaxone. Inhibition of this PBP leads to cell enlargement and the termination of septation (11). Ceftobiprole had better affinity than ceftriaxone for all PBPs except PBP2 (Table 2), whose inhibition leads to cell lysis (11).


View this table:
[in this window]
[in a new window]

  		TABLE 2. Binding of ceftobiprole, ceftriaxone, and ceftazidime to PBPs from gram-positive cocci

PBP2a from methicillin-resistant S. aureus strain OC 3726 (Table 2 and Fig. 2) had high affinity for ceftobiprole, unlike ceftriaxone and ceftazidime. Entenza et al. previously reported low ceftobiprole IC50s for PBP2a (≤0.47 µg/ml), which were >100 times lower than those for methicillin (8). Hebeisen et al. also reported potent binding of ceftobiprole to PBP2a from S. epidermidis (18).


Figure 2
View larger version (41K):
[in this window]
[in a new window]

  		FIG. 2. Affinity of PBP2a from S. aureus 3726 for ceftobiprole (BPR) or ceftazidime (CAZ). All samples except "C" were initially preincubated with 1 mg/ml of clavulanic acid to saturate all PBPs except PBP2a. For competition assays, ceftobiprole or ceftazidime was added at the indicated concentrations, followed by labeling with Bocillin FL. IC50 values were calculated by 50% inhibition of Bocillin FL binding compared to the no-drug (0 µg/ml) sample. Lane "C" contains PBPs labeled only with Bocillin FL in order to visualize all PBPs.

S. pneumoniae OC 8865 was penicillin susceptible and had no pbp1a, pbp2b, and pbp2x mutations. Ceftobiprole and ceftriaxone PBP-binding profiles were similar (Table 2), having high affinity for PBP1a and PBP2x, the primary cephalosporin targets (13, 22). Unexpectedly, ceftobiprole had good affinity for PBP2b (IC50 value of 0.06 µg/ml), unlike ceftriaxone, which had an IC50 of >1 µg/ml (Table 2). Studies have shown that cefotaxime, ceftriaxone, cefuroxime, and ceftazidime have poor affinity for PBP2b (13, 16, 22). The ceftobiprole affinity for PBP2b may be due to improved kinetic interactions as seen with the methicillin-resistant staphylococcus PBP2a (18).

In pneumococcal clinical isolates, β-lactam resistance is caused primarily by alterations in PBP1a, PBP2x, and PBP2b (1, 2, 15, 27). Penicillin- and ceftriaxone-resistant S. pneumoniae OC 8819 had the following substitutions: T371S to S and P432 to T in PBP1a; T338 to A, M339 to F, I371 to T, R384 to G, M400 to T, and L546 to V in PBP2x; and T446 to A and A619 to G in PBP2b. For PBP2x, ceftobiprole had an eightfold-higher binding affinity than ceftriaxone (Table 2). Heinze-Krauss et al. similarly reported that a ceftobiprole analog had IC50 values that were approximately sixfold lower than those of ceftriaxone against purified PBP2x from two cefotaxime-resistant isolates (19). Neither ceftobiprole nor ceftriaxone bound to PBP2b at concentrations of ≤8 µg/ml (Table 2), which was probably due to the PBP2b T446-to-A substitution known to contribute to penicillin resistance (13). Affinities for PBP1a, PBP2a, and PBP3 were similar for both drugs, but ceftriaxone had a higher affinity for PBP1b than did ceftobiprole (Table 2).

In summary, ceftobiprole demonstrated potent binding to PBPs from gram-positive bacteria, including those with decreased β-lactam sensitivity, such as PBP2a in MRSA and PBP2x in a penicillin-resistant S. pneumoniae strain, in contrast to ceftriaxone. In E. coli, ceftobiprole exhibited strong binding to the essential PBPs PBP2 and PBP3. Ceftobiprole exhibited a binding profile similar to those of cefepime and ceftazidime in P. aeruginosa but with enhanced binding to PBP2. These binding profiles explain the broad-spectrum activity for ceftobiprole that includes gram-negative bacteria and many β-lactam-resistant gram-positive cocci, including MRSA.


arrow
ACKNOWLEDGMENTS
 
This work was supported by Johnson & Johnson Pharmaceutical Research and Development, LLC, and Basilea Pharmaceutica AG.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research and Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869. Phone: (908) 707-3465. Fax: (908) 707-3501. E-mail: tdavies{at}prdus.jnj.com Back

{triangledown} Published ahead of print on 30 April 2007. Back


arrow
REFERENCES
 
    1
  1. Asahi, Y., Y. Takeuchi, and K. Ubukata. 1999. Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 43:1252-1255.[Abstract/Free Full Text]
    2. 2
  2. Asahi, Y., and K. Ubukata. 1998. Association of a Thr-371 substitution in a conserved amino acid motif of penicillin-binding protein 1A with penicillin resistance of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2267-2273.[Abstract/Free Full Text]
    3. 3
  3. Bogdanovich, T., C. Clark, L. Ednie, G. Lin, K. Smith, S. Shapiro, and P. C. Appelbaum. 2006. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50:2050-2057.[Abstract/Free Full Text]
    4. 4
  4. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.[Abstract/Free Full Text]
    5. 5
  5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
    6. 6
  6. Curtis, N. A. C., D. Orr, G. W. Ross, and M. G. Boulton. 1979. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob. Agents Chemother. 16:533-539.[Abstract/Free Full Text]
    7. 7
  7. Davies, T. A., W. Shang, and K. Bush. 2006. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP1a, PBP2b, and PBP2x. Antimicrob. Agents Chemother. 50:2530-2532.[Abstract/Free Full Text]
    8. 8
  8. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.[Abstract/Free Full Text]
    9. 9
  9. Fontana, R., M. Aldegheri, M. Ligozzi, G. Lo Cascio, and G. Cornaglia. 1998. Interaction of ceftriaxone with penicillin-binding proteins of Escherichia coli in the presence of human serum albumin. J. Antimicrob. Chemother. 42:95-98.[Abstract/Free Full Text]
    10. 10
  10. Georgopapadakou, N. H. 1993. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob. Agents Chemother. 37:2045-2053.[Free Full Text]
    11. 11
  11. Georgopapadakou, N. H., B. A. Dix, and Y. R. Mauriz. 1986. Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus. Antimicrob. Agents Chemother. 29:333-336.[Abstract/Free Full Text]
    12. 12
  12. Georgopapadakou, N. H., S. A. Smith, and R. B. Sykes. 1982. Mode of action of azthreonam. Antimicrob. Agents Chemother. 21:950-956.[Abstract/Free Full Text]
    13. 13
  13. Grebe, T., and R. Hakenbeck. 1996. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics. Antimicrob. Agents Chemother. 40:829-834.[Abstract]
    14. 14
  14. Gutmann, L., S. Vincent, D. Billot-Klein, J. F. Acar, E. Mrena, and R. Williamson. 1986. Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some β-lactam antibiotics alone and the synergistic lytic effect of amdinocillin (mecillinam). Antimicrob. Agents Chemother. 30:906-912.[Abstract/Free Full Text]
    15. 15
  15. Hakenbeck, R. 1999. β-Lactam-resistant Streptococcus pneumoniae. Epidemiology and evolutionary mechanism. Chemotherapy (Basel) 45:83-94.
    16. 16
  16. Hakenbeck, R., S. Tornette, and N. F. Adkinson. 1987. Interaction of non-lytic β-lactams with penicillin-binding proteins in Streptococcus pneumoniae. J. Gen. Microbiol. 133:755-760.[Abstract/Free Full Text]
    17. 17
  17. Hayes, M. V., and D. C. Orr. 1983. Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J. Antimicrob. Chemother. 12:119-126.[Abstract/Free Full Text]
    18. 18
  18. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.[Abstract/Free Full Text]
    19. 19
  19. Heinze-Krauss, I., P. Angehrn, P. Guerry, P. Hebeisen, C. Hubschwerlen, I. Kompis, M. G. P. Page, H. G. F. Richter, V. Runtz, et al. 1996. Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. J. Med. Chem. 39:1864-1871.[CrossRef][Medline]
    20. 20
  20. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.[Abstract/Free Full Text]
    21. 21
  21. Kosowska, K., D. B. Hoellman, G. Lin, C. Clark, K. Credito, P. McGhee, B. Dewasse, B. Bozdogan, S. Shapiro, and P. C. Appelbaum. 2005. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:1932-1942.[Abstract/Free Full Text]
    22. 22
  22. Munoz, R., C. G. Dowson, M. Daniels, T. J. Coffey, C. Martin, R. Hakenbeck, and B. G. Spratt. 1992. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae. Mol. Microbiol. 6:2461-2465.[Medline]
    23. 23
  23. Nichol, K. A., G. G. Zhanel, and D. J. Hoban. 2002. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:3261-3264.[Abstract/Free Full Text]
    24. 24
  24. Page, M. G. P., P. Caspers, and M. Kania. 2005. Interaction of ceftobiprole with a purified soluble form of Staphylococcus epidermidis PBP2'. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1157.
    25. 25
  25. Pucci, M. J., J. Boice-Sowek, R. E. Kessler, and T. J. Dougherty. 1991. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob. Agents Chemother. 35:2312-2317.[Abstract/Free Full Text]
    26. 26
  26. Sifaoui, F., M.-D. Kitzis, and L. Gutmann. 1996. In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral β-lactam antibiotics is associated with alterations of PBP2x. Antimicrob. Agents Chemother. 40:152-156.[Abstract]
    27. 27
  27. Smith, A. M., and K. P. Klugman. 1995. Alterations in penicillin-binding protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 39:859-867.[Abstract]
    28. 28
  28. Yang, Y., N. Bhachech, and K. Bush. 1995. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J. Antimicrob. Chemother. 35:75-84.[Abstract/Free Full Text]
    29. 29
  29. Zbinden, R., V. Punter, and A. Von Graevenitz. 2002. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob. Agents Chemother. 46:871-874.[Abstract/Free Full Text]
    30. 30
  30. Zhao, G., T. I. Meier, S. D. Kahl, K. R. Gee, and L. C. Blaszczak. 1999. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob. Agents Chemother. 43:1124-1128.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, July 2007, p. 2621-2624, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00029-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Llarrull, L. I., Fisher, J. F., Mobashery, S. (2009). Molecular Basis and Phenotype of Methicillin Resistance in Staphylococcus aureus and Insights into New {beta}-Lactams That Meet the Challenge. Antimicrob. Agents Chemother. 53: 4051-4063 [Full Text]  
  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  
  • Kosowska-Shick, K., McGhee, P., Appelbaum, P. C. (2009). Binding of Faropenem and Other {beta}-Lactam Agents to Penicillin-Binding Proteins of Pneumococci with Various {beta}-Lactam Susceptibilities. Antimicrob. Agents Chemother. 53: 2176-2180 [Abstract] [Full Text]  
  • Beltramini, A. M., Mukhopadhyay, C. D., Pancholi, V. (2009). Modulation of Cell Wall Structure and Antimicrobial Susceptibility by a Staphylococcus aureus Eukaryote-Like Serine/Threonine Kinase and Phosphatase. Infect. Immun. 77: 1406-1416 [Abstract] [Full Text]  
  • Bulitta, J. B., Ly, N. S., Yang, J. C., Forrest, A., Jusko, W. J., Tsuji, B. T. (2009). Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 46-56 [Abstract] [Full Text]  
  • Chung, M., Antignac, A., Kim, C., Tomasz, A. (2008). Comparative Study of the Susceptibilities of Major Epidemic Clones of Methicillin-Resistant Staphylococcus aureus to Oxacillin and to the New Broad-Spectrum Cephalosporin Ceftobiprole. Antimicrob. Agents Chemother. 52: 2709-2717 [Abstract] [Full Text]  
  • Banerjee, R., Gretes, M., Basuino, L., Strynadka, N., Chambers, H. F. (2008). In Vitro Selection and Characterization of Ceftobiprole-Resistant Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2089-2096 [Abstract] [Full Text]  
  • Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
  • Lemaire, S., Fuda, C., Van Bambeke, F., Tulkens, P. M., Mobashery, S. (2008). Restoration of Susceptibility of Methicillin-resistant Staphylococcus aureus to {beta}-Lactam Antibiotics by Acidic pH: ROLE OF PENICILLIN-BINDING PROTEIN PBP 2a. J. Biol. Chem. 283: 12769-12776 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»